A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment with Immunosuppressants.

Registry ID

EUCTR2009-014669-13

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Alexion Pharmaceuticals Inc.

Start date

2009-11-30

Completion date

2011-03-16

Last update

2026-08-16

Conditions

• Generalized Myasthenia Gravis (gMG)

Summary

• Treatment-emergent adverse events (TEAEs). • Percentage of patients with a 3-point reduction from baseline in the Quantitative Myasthenia Gravis (QMG) total score for disease severity.

Locations

• , , UK

Related clinical trials

• RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
• Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
• ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
• ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
• A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

View on source registry